Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02650674




Registration number
NCT02650674
Ethics application status
Date submitted
30/10/2015
Date registered
8/01/2016
Date last updated
14/09/2017

Titles & IDs
Public title
Determination of the Glycaemic Index and Insulinaemic Index Values of Five Cereal Products
Scientific title
Determination of the Glycaemic Index and Insulinaemic Index Values of Five Cereal Products
Secondary ID [1] 0 0
KBE043
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metabolic Disorder 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Metabolic disorders
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Product A: NP-0148
Other interventions - Glucose solution
Other interventions - Product B: NP-0149
Other interventions - Product C: NP-0150
Other interventions - Product D: NP-0151
Other interventions - Product E: NP-0152

Experimental: Product A: NP-0148 - Cereal product belVita Milk \& Cereals - High in SDS

Experimental: Product B: NP-0149 - Cereal product belVita Honey \& Nuts - High in SDS

Experimental: Product C: NP-0150 - Cereal product belVita Mixed Berry - High in SDS

Experimental: Product D: NP-0151 - Cereal product Kellogg's Corn Flakes - Low in SDS - Low in fat

Experimental: Product E: NP-0152 - Cereal product Kellogg's Trésor Duo Choco - Low in SDS

Experimental: Glucose reference - Glucose solution performed on three occasions


Other interventions: Product A: NP-0148
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.

Other interventions: Glucose solution
Glucose solution providing 50 g of available carbohydrates in 250 ml of water. This will be performed 3 times

Other interventions: Product B: NP-0149
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.

Other interventions: Product C: NP-0150
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.

Other interventions: Product D: NP-0151
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.

Other interventions: Product E: NP-0152
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Glycaemic index values of five cereal products
Timepoint [1] 0 0
2 hours after food consumption
Secondary outcome [1] 0 0
Glycaemic response assessed by the glycemic index (GI) values of five cereal products
Timepoint [1] 0 0
2 hours after food consumption
Secondary outcome [2] 0 0
Glycaemic response assessed by the postprandial changes in glycaemia over 2 hours (iAUC0-120) after consumption of the test products
Timepoint [2] 0 0
2 hours after food consumption
Secondary outcome [3] 0 0
Glycaemic response assessed by the kinetic of glycemia over the 120 minutes
Timepoint [3] 0 0
2 hours after food consumption
Secondary outcome [4] 0 0
Glycaemic response assessed by the peak value of glycemia
Timepoint [4] 0 0
2 hours after food consumption
Secondary outcome [5] 0 0
Glycaemic response assessed by the delta value between baseline and peak values of glycemia
Timepoint [5] 0 0
2 hours after food consumption
Secondary outcome [6] 0 0
Insulinaemic response assessed by the insulinemic index (II) values of five cereal products
Timepoint [6] 0 0
2 hours after food consumption
Secondary outcome [7] 0 0
Insulinaemic response assessed by the postprandial changes in insulinemia over 2 hours (iAUC0-120) after consumption of the test products
Timepoint [7] 0 0
2 hours after food consumption
Secondary outcome [8] 0 0
Insulinaemic response assessed by the kinetic of insulinemia over the 120 minutes
Timepoint [8] 0 0
2 hours after food consumption
Secondary outcome [9] 0 0
Insulinaemic response assessed by the peak value of insulinemia
Timepoint [9] 0 0
2 hours after food consumption
Secondary outcome [10] 0 0
Insulinaemic response assessed by the delta value between baseline and peak values of insulinemia
Timepoint [10] 0 0
2 hours after food consumption
Secondary outcome [11] 0 0
Insulin / glucose ratio (II/GI) evaluation of five cereal products
Timepoint [11] 0 0
2 hours after food consumption
Secondary outcome [12] 0 0
Postprandial changes in insulin / glucose over 2 hours (iAUC0-120) after consumption of the test products
Timepoint [12] 0 0
2 hours after food consumption
Secondary outcome [13] 0 0
Kinetic of insulin / glucose over the 120 minutes
Timepoint [13] 0 0
2 hours after food consumption
Secondary outcome [14] 0 0
Peak value of insulin / glucose ratio
Timepoint [14] 0 0
2 hours after food consumption
Secondary outcome [15] 0 0
Delta peak value between baseline and peak values of insulin / glucose ratio
Timepoint [15] 0 0
2 hours after food consumption

Eligibility
Key inclusion criteria
* Aged between 18-45 years.
* Non-smoker.
* BMI values: between 19-25 kg/m2 (bounds included) for Caucasian subjects and between 19-23 kg/m2 (bounds included) for Asian subjects (WHO expert consultation).
* Ethnicity: Caucasian subjects will have both parents from Caucasian ancestry. Asian subjects will have both parents from Asian country and will be born in an Asian country. Asian countries are: Brunei Darussalam, Cambodia, China, Dem. People's Republic of Korea, Hong Kong SAR (China), Indonesia, Japan, Lao People's Democratic Republic, Macao SAR (China), Malaysia, Mongolia, Myanmar, Philippines, Republic of Korea, Singapore, Taiwan, Thailand, Viet Nam.
* Sex ratio: Around half of the subjects should be male and half of the subjects should be female within each study group. A plus or minus 1 subject tolerance will be accepted.
* Healthy subjects with:

Normal glucose tolerance Normal laboratory values for various measures of metabolic health (full blood count, gamma-GT, AST, ALT, glucose, TAGs, total cholesterol, HDL-cholesterol, LDL-cholesterol); Normal systolic blood pressure (100-150 mmHg); Normal diastolic blood pressure (60-90 mmHg); Normal resting heart rate (50-90 beats per minutes after 3 minutes rest).

* Stable dietary habits; normal eating patterns; no history of eating disorders or strict dieting.
* Moderate level of physical activity (from basic daily activity to a high level of physical activity (regular physical activity at least 3 times per week))
* Able to fast for at least 10 hours the night before each test session.
* Able to refrain from eating legumes and drinking alcohol the day before each test session.
* Subject covered by social security or covered by a similar system
* Subject not taking any treatment for anorexia, weight loss, or any form of treatment likely to interfere with metabolism or dietary habits
* Subject having given written consent to take part in the study.
Minimum age
18 Years
Maximum age
45 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Following a restrictive diet.
* Family history of Diabetes Mellitus or obesity
* Suffering from any clinical, physical or mental illness.
* Suffering from any food allergies or hypersensitivities (wheat, milk, egg, nuts, etc).
* Taking any regular prescription medication at the time of inclusion (except regular oral contraception medication)
* Female who is pregnant (positive test results), lactating, planning pregnancy or not using acceptable contraceptive.
* Females who consistently suffer from premenstrual tension and marked changes in appetite during their menstrual cycle.
* Subject having taken part in another clinical trial within the last week.
* Subject currently taking part in another clinical trial or being in the exclusion period of another clinical trial.
* Subject undergoing general anaesthesia in the month prior to inclusion.
* Subject in a situation which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the subject.

Study design
Purpose of the study
Other
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
NA
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/04/2016
Sample size
Target
Accrual to date
Final
24
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
University of Sydney - Sydney
Recruitment postcode(s) [1] 0 0
2006 - Sydney

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Mondelez International, Inc.
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
University of Sydney
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Jennie Brand Miller
Address 0 0
University of Sydney
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT02650674